MaxCyte reports Q4 EPS (10c), consensus (12c)
Reports Q4 revenue $8.69M, consensus $7.91M. “We are pleased to report strong financial results in 2024, including a return to core revenue ...
MaxCyte (MXCT) Gets a Buy from Craig-Hallum
Craig-Hallum analyst Matt Hewitt maintained a Buy rating on MaxCyte (MXCT – Research Report) today. The company’s shares opened today at ...
ETF Daily News4d
Q1 Earnings Forecast for MaxCyte Issued By William Blair
View Our Latest Stock Analysis on MaxCyte MaxCyte Stock Performance MXCT stock opened at $3.06 on Thursday. The stock has a market cap of $324.23 million, a P/E ratio of -9.00 and a beta of 1.35 ...
Yahoo Finance6d
MaxCyte Inc (MXCT) Q4 2024 Earnings Call Highlights: Strategic Growth Amid Revenue Challenges
MaxCyte Inc (NASDAQ:MXCT) reported a strong year in 2024 with a return to core revenue growth and strategic improvements in operations. The acquisition of SecureDX is expected to enhance MaxCyte's ...
ETF Daily News9d
MaxCyte (MXCT) Expected to Announce Quarterly Earnings on Tuesday
10 Stocks to Sell NOW! 3 Stocks to DOUBLE This Year The 10 Best Stocks to Own in 2023 7 Stocks to Buy and Hold Forever MaxCyte, Inc, a life sciences company, discovers, develops, and ...
Investing6d
MaxCyte files annual report with SEC
ROCKVILLE, MD - MaxCyte, Inc. (NASDAQ:MXCT; LSE:MXCT), a company specializing in cell-engineering technologies for cell-based therapies, has filed its Form 10-K annual report for the fiscal year ...
London South East5d
MaxCyte reports wider loss, forecasts revenue growth in 2025
(Alliance News) - MaxCyte Inc on Tuesday said its annual loss widened amid higher costs and falling revenue, but it remains optimistic about growth prospects for 2025. The Rockville, Maryland ...
Investing6d
MaxCyte shares tumble as Q4 revenue plunges despite beating estimates
ROCKVILLE, MD - MaxCyte, Inc. (NASDAQ:MXCT) reported fourth quarter earnings that beat analyst expectations, but saw revenue plummet 45% YoY, sending shares down 10.4% in after-hours trading.
Yahoo Finance4d
MaxCyte, Inc. (MXCT)
MaxCyte Inc (MXCT) showcases strong core revenue growth and strategic acquisitions despite facing revenue declines and macroeconomic pressures. ROCKVILLE, Md., March 11, 2025 (GLOBE NEWSWIRE ...
Investing5d
MaxCyte core business revenue grows despite overall decline
ROCKVILLE, MD - MaxCyte, Inc. (NASDAQ: MXCT; LSE: MXCT), a cell-engineering company focused on enabling technologies for cell therapeutics, has reported a mixed financial outcome for the fourth ...
Morningstar6d
MaxCyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Guidance
MaxCyte is providing initial 2025 revenue guidance for core business revenue and SPL Program-related revenue: Core revenue is expected to grow 8% to 15% compared to 2024, inclusive of revenue from ...